<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-165932</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Invasive candidiasis in the neutropenic patient</dc:title>
<dc:description xml:lang="en">There are major differences in the epidemiology and prognosis of invasive candidiasis and candidemia in the neutropenic patient; however, a recent study performed in Spanish hospitals (Candipop) confirmed that mortality at 1 month is 30%, which is similar to that observed in the general population. Although Candida albicans is the most frequently isolated species, C. tropicalis, C. glabrata, and C. krusei are more prevalent than in non-neutropenic patients. The benefit of neutrophil transfusion is unclear, and catheter withdrawal must be tailored and based on confirmation of the diagnosis. Echinocandins are the first-line option for therapy and have a better safety profile than other agents (AU)</dc:description>
<dc:creator>Fortún, Jesús</dc:creator>
<dc:creator>Gioia, Francesca</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Existen diferencias significativas en la epidemiología y pronóstico de la candidemia y candidiasis invasiva en el paciente neutropénico, aunque una similar mortalidad a la observada en la población general (30% al mes) ha sido notificada en un reciente estudio nacional (Candipop). Candida albicans es la especie más frecuente pero C. tropicalis, C. glabrata y C. krusei tienen una mayor prevalencia que en los pacientes no neutropénicos. No está claro el beneficio de la transfusión de neutrófilos y la retirada de catéter debe ser individualizada. Las equinocandinas suponen el tratamiento de elección dada su eficacia y perfil de toxicidad en relación a otros antifúngicos (AU)</dc:description>
<dc:source>Rev Esp Quimioter;30(supl.1): 22-25, sept. 2017. tab</dc:source>
<dc:identifier>ibc-165932</dc:identifier>
<dc:title xml:lang="es">Candidasis invasiva en el paciente neutropénico</dc:title>
<dc:subject>^d9691^s22012</dc:subject>
<dc:subject>^d53932^s22057</dc:subject>
<dc:subject>^d53933^s22057</dc:subject>
<dc:subject>^d2208^s22021</dc:subject>
<dc:subject>^d53933^s22016</dc:subject>
<dc:subject>^d2208^s22001</dc:subject>
<dc:subject>^d36631^s22021</dc:subject>
<dc:subject>^d36630^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d943^s22073</dc:subject>
<dc:subject>^d52786^s22073</dc:subject>
<dc:subject>^d9692</dc:subject>
<dc:type>article</dc:type>
<dc:date>201709</dc:date>
</metadata>
</record>
</ibecs-document>
